GlassScriptPhysician profile
Adeeb Ahmed
NPI 1245217603
$25,955.71
in general payments reported to CMS, 2019-2025
28 companies · $341 in 2025
The $341 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $1,324 · 2021: $250 · 2022: $1,282 · 2023: $259 · 2024: $520 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11,742.33 | 2019-2023 | Xarelto |
| Regeneron Pharmaceuticals, INC. | $9,020.21 | 2019 | |
| Penumbra, INC. | $1,391.95 | 2022-2025 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $1,320.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $594.35 | 2019-2024 | |
| Pfizer INC. | $245.56 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $210.40 | 2019-2024 | Lifevest |
| Amgen INC. | $201.19 | 2019-2025 | Repatha, Repatha |
| Heartflow, INC. | $150.25 | 2023-2024 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.34 | 2019-2020 | |
| Lundbeck LLC | $127.52 | 2019-2020 | |
| Abbott Laboratories | $110.86 | 2025 | Dragonfly Opstar |
| Edwards Lifesciences Corporation | $110.04 | 2019 | |
| Irhythm Technologies, INC. | $105.46 | 2024 | Zio Monitor, Zio Xt Patch |
| Regeneron Healthcare Solutions, INC. | $90.49 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $69.29 | 2019 | |
| Tactile Systems Technology INC | $44.71 | 2024 | Flexitouch Plus, Entre Plus |
| Philips North America LLC | $39.04 | 2020 | |
| Boston Scientific Corporation | $33.61 | 2024 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $32.87 | 2023-2024 | |
| Pacira Pharmaceuticals Incorporated | $29.11 | 2019 | |
| Gilead Sciences, INC. | $26.39 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.26 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.08 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $21.60 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $16.03 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $15.00 | 2019 | |
| Amarin Pharma, INC. | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeeb Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.